Q4 2024 Neuland Laboratories Ltd Earnings Call Transcript
Key Points
- Neuland Laboratories Ltd (BOM:524558) reported a 30.8% increase in total income for FY24, reaching INR1,571.1 crores compared to INR1,200.9 crores in FY23.
- The company's EBITDA for FY24 stood at INR474.5 crores with a margin of 13.2%, reflecting a 6.8% increase over the previous year.
- The CMS business contributed close to 50% of the company's revenues, showing robust growth as key commercial products continue to scale.
- Neuland Laboratories Ltd (BOM:524558) reduced its net debt position to negative INR32.6 crores and improved its working capital cycle to 122 days from 141 days.
- The company has been actively investing in long-term growth CapEx, with INR143.7 crores invested during FY24, and continues to upgrade its facilities.
- The total income for Q4 FY24 was INR390.4 crores, a decrease from INR415.1 crores in Q4 FY23.
- EBITDA for Q4 FY24 was INR112.2 crores with a margin of 28.7%, a decrease of 2.02% compared to Q4 FY23.
- Profit after tax for Q4 FY24 was INR67.6 crores, down from INR84.5 crores in Q4 FY23.
- The company expects FY25 to be a year of normalized revenue and margin due to ongoing investments and input cost increases.
- There is a potential for moderation in revenue growth and normalization of margins in the short run due to the investments being made in the business.
Ladies and gentlemen, good day, and welcome to the Neuland Laboratories Limited Q4 and FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Ravi Udeshi from Ernst & Young. Thank you, and over to you, sir.
Thank you, Muskan. Good morning, friends. We welcome you to the Q4 and FY24 earnings conference call of Neuland Laboratories Limited.
To take us through the results and to answer your questions, we have with us today the top management from Neuland Laboratories, represented by Mr. Sucheth Davuluri, Vice Chairman and CEO; Mr. Saharsh Davuluri, Vice Chairman and Managing Director; Mr. Abhijit Majumdar, CFO; and Mr. Sajeev Emmanuel Medikonda, Head, Corporate Planning and Strategy.
We will start the call with a brief overview of the financials by Mr. Abhijit Majumdar, and then Saharsh will give you broad highlights of the business trends and what is above in the market. And post this, we will open up the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
